| Full text | |
| Author(s): |
Gutierrez, Victor
[1]
;
Seabra, Amedea B.
[2]
;
Reguera, Rosa M.
[3]
;
Khandare, Jayant
[4]
;
Calderon, Marcelo
[1]
Total Authors: 5
|
| Affiliation: | [1] Free Univ Berlin, Inst Chem & Biochem, D-14195 Berlin - Germany
[2] Univ Fed Sao Paulo, Exact & Earth Sci Dept, Sao Paulo - Brazil
[3] Univ Leon, Dept Ciencias Biomed, E-24071 Leon - Spain
[4] Maharashtra Inst Pharm, Pune 411038, Maharashtra - India
Total Affiliations: 4
|
| Document type: | Review article |
| Source: | CHEMICAL SOCIETY REVIEWS; v. 45, n. 1, p. 152-168, 2016. |
| Web of Science Citations: | 35 |
| Abstract | |
Leishmaniasis, a vector-borne disease caused by obligate intramacrophage protozoa, threatens 350 million people in 98 countries around the world. There are already 12 million infected people worldwide and two million new cases occur annually. Leishmaniasis has three main clinical presentations: cutaneous (CL), mucosal (ML), and visceral (VL). It is considered an opportunistic, infectious disease and the HIV-leishmaniasis correlation is well known. Antimonial compounds are used as first-line treatment drugs, but their toxicity, which can be extremely high, leads to a number of undesirable side effects and resultant failure of the patients to adhere to treatment. There is also a reported increase in Leishmania sp. resistance to these drugs. Nanotechnology has emerged as an attractive alternative because of its improved bioavailability and lower toxicity, and other characteristics that help to relieve the burden of this disease. In this review we will present some of the recent advances in the nanotechnological research regarding the treatment of leishmaniasis. The preclinical results regarding the approaches for a biomedical treatment of the disease have been encouraging, but further efforts will still be necessary for this therapy to have greater clinical applicability in humans. (AU) | |
| FAPESP's process: | 12/17053-7 - Nitric oxide releasing nanoparticles for biomedical applications |
| Grantee: | Amedea Barozzi Seabra |
| Support Opportunities: | Regular Research Grants |